Inmunoterapia con alérgenos, ¿cuándo y por qué?

Autores/as

  • Libia Susana Díez Zuluaga Universidad de Antioquia
  • Ricardo Cardona Villa Universidad de Antioquia
  • María Nelly Restrepo Colorado Clínica Medellín
  • Jorge Mario Sánchez Caraballo Universidad de Antioquia

Palabras clave:

alérgenos, atopia, asma, conjuntivitis, dermatitis, eczema, himenópteros, hipersensibilidad, inmunoterapia, modulación, rinitis

Resumen


La inmunoterapia específica con alérgenos es el único tratamiento que modifica el curso natural de algunas enfermedades alérgicas como asma, rinitis, conjuntivitis, dermatitis atópica y alergia al veneno de himenópteros. Sin embargo, aún existe cierta controversia respecto a su seguridad y su utilidad clínica. En el presente artículo se presenta una revisión de los mecanismos moleculares, las indicaciones y contraindicaciones de dicha inmunoterapia, y se evalúan su seguridad y eficacia en cada una de estas enfermedades mediante casos ilustrativos y una breve revisión del tema.

|Resumen
= 235 veces | PDF
= 122 veces|

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Biografía del autor/a

Libia Susana Díez Zuluaga, Universidad de Antioquia

Alergólogo Clínico, IPS Universitaria, Universidad de Antioquia, Medellín, Colombia.  

Ricardo Cardona Villa, Universidad de Antioquia

Alergólogo Clínico, IPS Universitaria, Universidad de Antioquia, Medellín, Colombia.

María Nelly Restrepo Colorado, Clínica Medellín

Alergóloga Clínica, Clínica Medellín, Medellín, Colombia.  

Jorge Mario Sánchez Caraballo, Universidad de Antioquia

Alergólogo Clínico, IPS Universitaria, Universidad de Antioquia. Gerente de proyectos, Fundación para el Desarrollo de las Ciencias Biológicas (FUNDEMEB), Medellín, Colombia. 

Citas

(1.) Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558–62.

(2.) Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1–55.

(3.) Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy. 2011 Jun;66(6):725–32.

(4.) Shamji MH, James LK, Durham SR. Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am. 2011 May;31(2):311–23, x.

(5.) van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum IgE-facilitated allergen presentation. J Immunol. 1999 Sep 1;163(5):2944–52.

(6.) Platts-Mills TA, von Maur RK, Ishizaka K, Norman PS, Lichtenstein LM. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest. 1976 Apr;57(4):1041–50.

(7.) Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B. Clin Exp Allergy.

Apr;40(4):598–606.

(8.) Johnson BA, Baban B, Mellor AL. Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy. 2009 Jul;1(4):645–61.

(9.) Soyer OU, Akdis M, Akdis CA. Mechanisms of subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am. 2011 May;31(2):175– 90, vii–viii.

(10.) Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008 Nov;29(5):771–81.

(11.) Bellinghausen I, König B, Böttcher I, Knop J, Saloga J. Inhibition of human allergic T-helper type 2 immu-ne responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction. Clin Exp Allergy. 2006 Dec;36(12):1546–55.

(12.) Müller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee ve-nom. Allergy. 1989 Aug;44(6):412–8.

(13.) Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, Malolepszy J, et al. Histamine regulates T-cell and an-tibody responses by differential expression of H1 and H2 receptors. Nature. 2001 Sep 27;413(6854):420–5.

(14.) Wilson DR, Irani AM, Walker SM, Jacobson MR, Mac-kay IS, Schwartz LB, et al. Grass pollen immunothe-rapy inhibits seasonal increases in basophils and eo-sinophils in the nasal epithelium. Clin Exp Allergy. 2001 Nov;31(11):1705–13.

(15.) Durham SR, Ying S, Varney VA, Jacobson MR, Sudde-rick RM, Mackay IS, et al. Grass pollen immunothe-rapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing mes-senger RNA for interferon-gamma. J Allergy Clin Im-munol. 1996 Jun;97(6):1356–65.

(16.) Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen im-munotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004 Mar 1;172(5):3252–9.

(17.) Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008 Feb;121(2):512–518.e2.

(18.) Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and Aller-Gen). Allergy. 2008 Apr;63(Suppl 86):8–160.

(19.) Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010 Nov;126(5):969–75.

(20.) Purello-D’Ambrosio F, Gangemi S, Merendino RA, Iso-la S, Puccinelli P, Parmiani S, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy. 2001 Aug;31(8):1295–302.21.

(21.) Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term preventive effect of seasonal and pe-rennial asthma: 10-year follow-up on the PAT study. Allergy. 2007 Aug;62(8):943-8.

(22.) Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane database Syst Rev. 2010 Jan;(8):CD001186.

(23.) Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane database Syst Rev. 2007 Jan;(1):CD001936.

(24.) Krishna MT, Ewan PW, Diwakar L, Durham SR, Frew AJ, Leech SC, et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guideli-nes. Clin Exp Allergy. 2011 Sep;41(9):1201–20.

(25.) Raap U, Wagenmann M, Pfaar O. [Allergen-specific immunotherapy in pet allergy - an update]. Hau-tarzt. 2011 Sep;62(9):657–62.

(26.) Kuna P, Kaczmarek J, Kupczyk M. Efficacy and sa-fety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol. 2011 Feb;127(2):502–508.e1–6.

(27.) Cortellini G, Spadolini I, Patella V, Fabbri E, Santucci A, Severino M, et al. Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. Ann Allergy Asthma Immu-nol. 2010 Nov;105(5):382–6.

(28.) Dreborg S, Agrell B, Foucard T, Kjellman NI, Koi-vikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986 Feb;41(2):131–40.

(29.) Gastaminza G, Algorta J, Uriel O, Audicana MT, Fer-nandez E, Sanz ML, et al. Randomized, double-blind, placebo-controlled clinical trial of sublingual immunotherapy in natural rubber latex allergic patients. Trials. 2011 Jan;12:191.

(30.) Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013 Nov;13(11):1543–56.

(31.) Tankersley MS, Butler KK, Butler WK, Goetz DW. Lo-cal reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol. 2000 Nov;106(5):840–3.

(32.) Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009 Dec;103(6):451–59; quiz 459–61, 495.

(33.) Bernstein DI, Epstein T. Systemic reactions to subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am. 2011 May;31(2):241–9, viii–ix.

(34.) Lang DM. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy? Curr Aller-gy Asthma Rep. 2008 Mar;8(1):37–44.

(35.) Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978 Jul 27;299(4):157–61.

(36.) Rodríguez Pérez N, Ambriz Moreno M de J. [Safety of im-munotherapy and skin tests with allergens in children younger than five years]. Rev Alerg Mex. 53(2):47–51.

(37.) Finegold I. Immunotherapy: when to initiate treatment in children. Allergy Asthma Proc. 28(6):698–705.

(38.) Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. Int Arch Allergy Immunol. 2004 Dec;135(4):332–5.

(39.) Shaikh WA. A retrospective study on the safety of immunotherapy in pregnancy. Clin Exp Allergy. 1993 Oct;23(10):857–60.

(40.) Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995 Apr;151(4):969–74.

(41.) Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010 Nov;126(5):942–9.

(42.) Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: sys-tematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006 Oct;61(10):1162–72.

(43.) Penagos M, Passalacqua G, Compalati E, Baena-Cag-nani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008 Mar;133(3):599–609.

(44.) Cox L. Allergen immunotherapy and asthma: efficacy, safety, and other considerations. Allergy Asthma Proc. 29(6):580–9.

(45.) Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seaso-nal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002 Feb;109(2):251–6.

(46.) Noon, L, Cantab, BC, Eng, FROS. Prophylactic Inoculation Against Hay Fever. The Lancet. 1911 Jun;177(4580):1572–3.

(47.) Freeman J. Further Observations on the treatment of hay fever by hipodermic inoculations of pollen vaccines. Lancet.

(48.) Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Co-chrane database Syst Rev. 2010 Jan;(12):CD002893.

(49.) Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, et al. Efficacy of sublin-gual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006 Aug;97(2):141-8.

(50.) Olaguíbel JM, Alvarez Puebla MJ. Efficacy of sublin-gual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J In-vestig Allergol Clin Immunol. 2005 Jan;15(1):9–16.

(51.) Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for hou-se dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009 Nov;64(11):1570–9.

(52.) Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2010 Sep;126(3):558–66.

(53.) Jedrzejczak-Czechowicz M, Lewandowska-Polak A, Jarzebska M, Kowalski ML. Mast cell and eosinophil activation during early phase of grass pollen-indu-ced ocular allergic reaction. Allergy Asthma Proc. 2011 Jan-Feb; 32(1):43–8.

(54.) Mortemousque B, Bertel F, De Casamayor J, Verin P, Colin J. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy. 2003 Apr;33(4):464–9.

(55.) Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483–94.

(56.) Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, et al. Efalizumab for severe atopic der-matitis: a pilot study in adults. J Am Acad Dermatol. 2007 Feb;56(2):222–7.

(57.) Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007 Jul;120(1):164–70.

(58.) Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006 Dec;118(6):1292–8.

(59.) Bussmann C, Maintz L, Hart J, Allam J-P, Vrtala S, Chen K-W, et al. Clinical improvement and immuno-logical changes in atopic dermatitis patients under-going subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy. 2007 Sep;37(9):1277–85.

(60.) Einarsson R, Dreborg S, Hammarström L, Löfkvist T, Smith CI, Svensson G. Monitoring of mite Derma-tophagoides farinae allergen-specific IgG and IgG subclass distribution in patients on immunotherapy. Allergy. 1992 Apr;47(2 Pt 1):76–82.

(61.) Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006 Feb;61(2):202–5.

(62.) Sánchez Caraballo JM, Cardona Villa R. Clinical and immunological changes of immunotherapy in patients with atopic dermatitis: randomized controlled trial. ISRN Allergy. 2012 Jan;2012:183983.

(63.) Severino M, Bonadonna P, Passalacqua G. Large local reactions from stinging insects: from epidemiology to management. Curr Opin Allergy Clin Immunol. 2009 Aug;9(4):334–7.

(64.) Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol. 2008 Feb;100(2):162–5.

(65.) Golden DBK. Long-term outcome after venom immunotherapy. Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):337–41.

(66.) Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005 Dec;60(12):1459–70.

(67.) Incorvaia C, Frati F, Dell’Albani I, Robino A, Cattaneo E, Mauro M, et al. Safety of hymenoptera venom immunotherapy: a systematic review. Expert Opin Pharmacother. 2011 Nov;12(16):2527–32.

(68.) Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992 Feb;89(2):529–35.

Descargas

Publicado

2014-12-29

Cómo citar

1.
Díez Zuluaga LS, Cardona Villa R, Restrepo Colorado MN, Sánchez Caraballo JM. Inmunoterapia con alérgenos, ¿cuándo y por qué?. Iatreia [Internet]. 29 de diciembre de 2014 [citado 28 de junio de 2022];28(1):55-6. Disponible en: https://revistas.udea.edu.co/index.php/iatreia/article/view/17755

Número

Sección

Artículos de revisión

Artículos más leídos del mismo autor/a

1 2 > >> 

Artículos similares

1 2 3 4 5 6 7 8 9 10 > >> 

También puede Iniciar una búsqueda de similitud avanzada para este artículo.